<DOC>
	<DOCNO>NCT00801723</DOCNO>
	<brief_summary>Randomized , double-blind , comparative study versus placebo perform patient study CB-01-02/01 ( NCT00679432 ) , CB-01-02/02 ( NCT00679380 ) , CB-01-02/06 ( NCT01100112 ) achieve ulcerative colitis disease activity index ( UCDAI ) remission 8 week treatment . Patients remission End Study visit give opportunity enter 12-month Maintenance Phase study outline protocol ( CB-01-02/04 ) . The End Study visit study 01 , 02 , 06 set Visit 1 ( Day 0 ) study . There interruption study treatment parent study study . It plan approximately 150 patient enrol study . Patients randomly assign two group receive either budesonide MMX 6 mg placebo irrespective treatment assign study 01 , 02 , 06 . Treatments administer day breakfast maximum 12 month occurrence first clinical relapse , clinical relapse define combined recurrence rectal bleed stool frequency ≥ 1-2 stools/day normal patient ( score ≥ 1 UCDAI item ) . During study , patient assess safety efficacy Visit 1 1 , 3 , 6 , 9 , 12 month treatment . Patients contact telephone monthly basis safety assessment . In case occurrence symptom suggestive clinical relapse , patient attend unscheduled visit time study .</brief_summary>
	<brief_title>( CB-01-02/04 ) Extension Study Budesonide Multi-Matrix System ( MMX ) 6 mg Maintenance Of Remission In Patients With Ulcerative Colitis .</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients fulfil follow criterion eligible participation study : Male female patient , 1875 year old , able understand voluntarily provide write informed consent . Patients UCDAI remission define UCDAI score ≤ 1 point score 0 rectal bleed stool frequency , ≥ 1 point reduction baseline endoscopy score without sign mucosal friability ( score 0 mucosal appearance ) . Patients complete End Study assessment CB0102/01 , CB0102/02 CB0102/06 study . Females childbearing potential must serum pregnancy test perform End Study visit parent study must use acceptable contraceptive method throughout study treatment period . Patients meet follow criterion screen visit exclude study participation : Subjects withdraw study CB0102/01 , CB 01 02/02 CB0102/06 . Subjects achieve induction remission accord primary endpoint definition study CB0102/01 , CB 01 02/02 CB0102/06 ( i.e . clinical remission define UCDAI score ≤ 1 point score 0 rectal bleed stool frequency , ≥ 1 point reduction baseline endoscopy score without sign mucosal friability [ score 0 mucosal appearance ] ) . Subjects bone density lower normal age sex ( Tscore low 1 ) assess via dual energy Xray absorptiometry ( DXA ) scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Ulcerative Colitis</keyword>
</DOC>